Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 2:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 908 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Age-related Macular Degeneration (AMD) Clear all
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT03802630
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
26
States / cities
Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 9, 2026, 2:48 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration

NCT03930641
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
RTH258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Altamonte Springs, Florida • Pensacola, Florida • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 9, 2026, 2:48 PM EDT
Not listed Phase 2 Interventional

The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration (Dry AMD)

NCT00485394
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
OT-551, vehicle placebo
Drug
Lead sponsor
Othera Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
17
States / cities
Mesa, Arizona • Tucson, Arizona • Beverly Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Oct 9, 2026, 2:48 PM EDT
Recruiting No phase listed Observational

Imaging Retinal Vasculature in Infant Eyes

NCT05558059
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Handheld Optical Coherence Tomography with OCT Angiography
Device
Lead sponsor
Duke University
Other
Eligibility
Up to 2 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 9, 2026, 2:48 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Carbidopa-Levodopa in Dry AMD With Geographic Atrophy

NCT03451500
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
carbidopa-levodopa
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 9, 2026, 2:48 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration

NCT00395707
View directory record Official record
Conditions
Macular Degeneration
Interventions
Lucentis, Ranibizumab, Ranibizumab (Lucentis)
Drug
Lead sponsor
The National Retina Institute
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
2
States / cities
Chevy Chase, Maryland • Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 9, 2026, 2:48 PM EDT
Completed No phase listed Observational

Genetic Load and Phenotype in Aggressive AMD

NCT01650948
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
RetnaGene AMD LDT
Device
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2014 · Synced Oct 9, 2026, 2:48 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Post-Approval Study of the Implantable Miniature Telescope

NCT01757132
View directory record Official record
Conditions
AMD
Interventions
Implantable Miniature Telescope
Device
Lead sponsor
VisionCare, Inc.
Industry
Eligibility
65 Years and older
Enrollment
770 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2028
U.S. locations
16
States / cities
Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 9, 2026, 2:48 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations

NCT05686421
View directory record Official record
Conditions
Age-Related Macular Degeneration, Diabetic Retinopathy, Central Serous Chorioretinopathy, Glaucoma, Glaucoma, Suspect, Eye Diseases
Interventions
OCT Imaging Using Device N, OCT Imaging Using Device C
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 9, 2026, 2:48 PM EDT
Recruiting Phase 1Phase 2 Interventional

Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration

NCT04339764
View directory record Official record
Conditions
Dry Age-Related Macular Degeneration, Geographic Atrophy
Interventions
iPSC-derived RPE/PLGA transplantation
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 95 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 9, 2026, 2:48 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT06635148
View directory record Official record
Conditions
Geographic Atrophy, Macular Degeneration
Interventions
JNJ-81201887, Sham Procedure
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
60 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
45
States / cities
Tucson, Arizona • Fullerton, California • La Jolla, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 9, 2026, 2:48 PM EDT
Completed No phase listed Observational Results available

Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study

NCT05131646
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
CLS-AX
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Mountain View, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 9, 2026, 2:48 PM EDT
Terminated Phase 2 Interventional Results available

An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy

NCT01602120
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Lampalizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
60 Years to 89 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
41
States / cities
Tucson, Arizona • Beverly Hills, California • Campbell, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 9, 2026, 2:48 PM EDT
Terminated Phase 2 Interventional Results available

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

NCT01471054
View directory record Official record
Conditions
Macular Edema, Cystoid Macular Edema, Uveal Melanoma, Radiation Maculopathy, Radiation Retinopathy
Interventions
Ozurdex, Bevacizumab
Drug
Lead sponsor
Arman Mashayekhi
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Oct 9, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration

NCT02510794
View directory record Official record
Conditions
Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Encino, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 9, 2026, 2:48 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Quest to Analyze One Thousand Humans Meditating

NCT06583395
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
Interventions
Advanced multi-component meditation practice
Behavioral
Lead sponsor
Tobias Moeller-Bertram
Industry
Eligibility
21 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palm Desert, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 9, 2026, 2:48 PM EDT
Completed Phase 2 Interventional

Study of STG-001 in Subjects With Stargardt Disease

NCT04489511
View directory record Official record
Conditions
Stargardt Disease-1
Interventions
STG-001
Drug
Lead sponsor
Stargazer Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Phoenix, Arizona • Gainesville, Florida • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 9, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)

NCT01331005
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
nepafenac 0.1% drops, Nepafenac Vehicle
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Loma Linda, California • Palm Springs, California • Santa Barbara, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 9, 2026, 2:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections

NCT02951351
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Macular Edema, Injection Site, Injection Site Infection, Pain, Postoperative
Interventions
Proparacaine, Conjunctival culture
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 9, 2026, 2:48 PM EDT
Completed Not applicable Interventional Results available

The Zeaxanthin and Visual Function Study

NCT00564902
View directory record Official record
Conditions
Age Related Macular Degeneration, Cognition Disorders
Interventions
3R 3'R Zeaxanthin, Lutein, Lutein and Zeaxanthin
Drug · Dietary Supplement
Lead sponsor
Chrysantis, Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Oct 9, 2026, 2:48 PM EDT
No Longer Available No phase listed Expanded access

Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate

NCT00349739
View directory record Official record
Conditions
Macular Degeneration
Interventions
Anecortave Acetate
Drug
Lead sponsor
University of Iowa
Other
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 9, 2026, 2:48 PM EDT
Completed No phase listed Observational

Repository for Inherited Eye Diseases

NCT00378742
View directory record Official record
Conditions
Retinitis Pigmentosa, Inherited Ophthalmic Diseases
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
1 Day to 100 Years
Enrollment
6,618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 9, 2026, 2:48 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration

NCT00764738
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
OCT, Multifocal ERG, Microperimetry, Ranibizumab Ophthalmic
Device · Drug
Lead sponsor
Retina Macula Institute
Other
Eligibility
50 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 9, 2026, 2:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparative Effectiveness of Vitamin D and Repletion Strategies

NCT01524874
View directory record Official record
Conditions
Hypovitaminosis D, Insulin Resistance, Diabetes
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
Bastyr University
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Kailua-Kona, Hawaii • Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 9, 2026, 2:48 PM EDT